Sarpogrelate Sustained Release/Aspirin + Aspirin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sarpogrelate
Conditions
Sarpogrelate, Blood Viscosity, Peripheral Arterial Disease, Coronary Artery Disease
Trial Timeline
Jan 11, 2023 → Feb 28, 2024
NCT ID
NCT05730621About Sarpogrelate Sustained Release/Aspirin + Aspirin
Sarpogrelate Sustained Release/Aspirin + Aspirin is a approved stage product being developed by Yuhan for Sarpogrelate. The current trial status is completed. This product is registered under clinical trial identifier NCT05730621. Target conditions include Sarpogrelate, Blood Viscosity, Peripheral Arterial Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05730621 | Approved | Completed |
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85